Reaction
Lack Of Injection Site Rotation reporting signals
As of the last recalculation, Lack Of Injection Site Rotation appears in 1,700 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is NALTREXONE (PRR 45.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Naltrexone | 107 | 45.3 | 45.4 |
| Lanreotide Acetate | 17 | 26.8 | 26.9 |
| Dupilumab | 624 | 24.5 | 24.5 |
| Evolocumab | 194 | 16.4 | 16.4 |
| Peginterferon Beta-1A | 16 | 15.1 | 15.1 |
| Glatiramer Acetate | 53 | 11.2 | 11.2 |
| Interferon Beta-1B | 16 | 10.3 | 10.3 |
| Interferon Beta-1A | 145 | 10.0 | 10.0 |
| Asfotase Alfa | 8 | 9.8 | 9.8 |
| Somatropin | 52 | 8.9 | 8.9 |
| Fremanezumab-Vfrm | 7 | 7.5 | 7.5 |
| Romosozumab-Aqqg | 7 | 6.3 | 6.3 |
| Erenumab-Aooe | 27 | 6.1 | 6.1 |
| Paliperidone Palmitate | 9 | 3.4 | 3.4 |
| Alirocumab | 7 | 3.4 | 3.4 |
| Sarilumab | 5 | 2.3 | 2.3 |